Table 3.

Association between serum CA125, HE4, and ROMA levels and clinicopathologic characteristics of patients with EOC

NCA125 medianPHE4 medianPROMA medianP
Stage
 Early stages (I–II)3388.3<0.0001116.5<0.000147.6<0.0001
 Late stages (III–IV)80658.3482.197.0
 Unknown1
Grade
 G1 + G220133.90.0579101.70.001947.00.0101
 G383542.9438.094.6
 Unknown11
Residual tumor, cm
 046129.7<0.0001167.1<0.000173.5<0.0001
 >0441,040.3629.997.2
 Unknown24
Histologic subtype
 Serous papillary51769.7<0.0001488.1<0.000197.4<0.0001
 Endometrioid17122.6168.273.5
 Clear cell10228.6200.280.0
 Mucinous873.166.320.6
 Undifferentiated81,553.2476.2595.6
 Mixed15746.7491.5090.2
 Unknown5
Presence of ascites
 No44112.9<0.0001154.2<0.000164.2<0.0001
 Yes581,110.8760.898.3
 Unknown12
Cytology
 Negative19141.70.0001168.20.004273.50.0005
 Positive63961.2488.197.0
 Unknown32
Lymph nodal involvement
 Negative35171.00.0009169.40.004073.50.0004
 Positive34764.1460.696.4
 Unknown45
Age, y
 <5027171.50.0311169.30.002274.20.002
 ≥5087563.8438.095.3